IMMU-08. PHASE I TRIAL (NCT02457845) SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF IMMUNOVIROTHERAPY WITH HSV G207 IN CHILDREN WITH PROGRESSIVE MALIGNANT SUPRATENTORIAL BRAIN TUMORS

ABSTRACT: Abstract

BACKGROUND

Outcomes for children with progressive malignant supratentorial brain tumors are dismal. Preclinical evidence indicates that pediatric brain tumors are highly sensitive to genetically engineered oncolytic HSV-1 G207, which lacks genes essential for replication in normal brain. We report on this first-in-children oncolytic virotherapy brain tumor trial of G207.

DESIGN/METHODS

A 3 + 3 design was used to evaluate the safety, tolerability and preliminary efficacy of G207 at two doses (107 and 108 plaque-forming units). After informed consent, patients underwent biopsy to confirm viable tumor followed by placement of up to four silastic intratumoral catheters. The following day, G207 was infused by convection enhanced delivery over 6 hours. Patients were as

SUBMITTER: Friedman G 

PROVIDER: S-EPMC6012830 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature